| John Evans |
John Evans is currently the Chief Executive Officer & Director at Beam Therapeutics, Inc. He is also the Chief Executive Officer at Blink Therapeutics, Inc. and a Director at Orbital Therapeutics, Inc. In the past, he worked as a Director at Verve Therapeutics, Inc. and Prime Medicine, Inc. He was also a Venture Partner at ARCH Venture Partners LLC and Vice President-Business Development & Operations at Agios Pharmaceuticals, Inc. Additionally, he worked as a Senior Associate at McKinsey & Co., Inc. and as an Investor Relations Contact at Infinity Pharmaceuticals, Inc. Mr. Evans holds a graduate degree from the University of Pennsylvania and an undergraduate degree from Yale University. He also holds an MBA from The Wharton School of the University of Pennsylvania. |
| John Lo |
John Lo is currently the Chief Commercial Officer at Beam Therapeutics, Inc. He holds a doctorate degree from the Massachusetts Institute of Technology. |
| Gopi Shanker |
Gopi Shanker is currently the Chief Scientific Officer at Beam Therapeutics, Inc. He previously held the position of Chief Scientific Officer at Tevard Biosciences, Inc. and Head-Neuroscience Disease Area at Novartis Institutes of Biomedical Research. Dr. Shanker obtained a doctorate degree from the Indian Institute of Science, a graduate degree from Madurai Kamaraj University, and an undergraduate degree from Osmania University. |
| Amy Simon |
Amy Simon is currently the Chief Medical Officer at Beam Therapeutics, Inc. She previously worked as the Vice President of Clinical Development at Alnylam Pharmaceuticals, Inc. and as a Professor at both Tufts University and the Graduate School of Biomedical Sciences. She received her undergraduate degree from Harvard University and her doctorate from Tufts University School of Medicine. |
| Manmohan Singh |
Manmohan Singh is currently the Chief Technology Officer at Beam Therapeutics, Inc. He previously worked as the Senior Director at Takeda Pharmaceuticals U.S.A., Inc. from 2016 to 2018 and as the Head-Formulation Development at Novartis Services, Inc. from 2008 to 2016. He also held the position of Global Head-Drug Product Development at Takeda Vaccines, Inc. |
| Brian Riley |
Brian Riley is currently the Chief Manufacturing Officer at Beam Therapeutics, Inc. He previously worked as the Site Director at Durham & Co. and as the Vice President-Operations at Catalent Pharma Solutions, Inc. Mr. Riley holds an MBA from Campbell University and an undergraduate degree from North Carolina State University. |
| Susan O'Connor |
Susan O'Connor is the founder of O'Connor & Associates, which was founded in 2008. She is currently the Chief Human Resources Officer at Beam Therapeutics, Inc. since 2017. Ms. O'Connor has held former positions as Vice President-Human Resources at Johnson & Johnson, Partner at Third Rock Ventures LLC, Chief Human Resources Officer at Blueprint Medicines Corp., Chief Human Resources Officer at Fulcrum Therapeutics, Inc., Chief Human Resources Officer at Relay Therapeutics, Inc., Chief Human Resources Officer at Magenta Therapeutics, Inc., and Chief Human Resources Officer at Celsius Therapeutics, Inc. She received her undergraduate degree from Providence College. |
| Terry-Ann Burrell |
Terry-Ann Burrell is an Independent Director at Recursion Pharmaceuticals, Inc. since 2020. She is also a Director at Rapport Therapeutics, Inc. since 2024. Previously, she served as the Chief Financial Officer & Treasurer at Beam Therapeutics, Inc. from 2019 to present. Prior to her current roles, she worked as a Managing Director at JPMorgan Securities LLC from 2008 to 2019. Ms. Burrell completed her undergraduate degree at Harvard University and holds an MBA from The Leonard N Stern School of Business. |
| Suzanne Fleming |
Suzanne Fleming is currently the Chief Accounting Officer at Beam Therapeutics, Inc. She previously held positions as the Senior Director-Finance at TransForm Pharmaceuticals, Inc. from 2003 to 2005, Principal at Transkaryotic Therapies, Inc., Principal at Oculon Corp from 1991 to 1995, Principal at CytoTherapuetics, Inc. from 1995 to 1998, Vice President-Finance at AVEO Pharmaceuticals, Inc. from 2005 to 2013, Treasurer, Chief Financial & Accounting Officer at Epizyme, Inc. from 2017 to 2019, and Vice President-Finance at Foundation Medicine, Inc. from 2014 to 2017. She obtained her undergraduate degree from Stonehill College, Inc. |
| Giuseppe Ciaramella |
Giuseppe Ciaramella is the founder of Orbital Therapeutics, Inc. He currently holds positions as a Member at the Infectious Diseases Society of America, a Member at the American Society of Gene Therapy, and as the President of Beam Therapeutics, Inc. Previously, he served as the Executive Director at AstraZeneca LP from 2011 to 2014, the Head-Biotherapeutics, Antivirals & Lead Discovery at Pfizer Group Ltd., the Vice President & Head-Collaborative Research at Boehringer Ingelheim Corp. from 2010 to 2011, and the Chief Scientific Officer-Infectious Diseases at Moderna, Inc. from 2014 to 2018. He obtained his doctorate degree from University College London. |
| Carole Ho |
Carole Ho is an Independent Director at Beam Therapeutics, Inc. since 2018 and the Chief Medical Officer & Head-Development at Denali Therapeutics, Inc. since 2015. She previously worked as a Medical Director at Johnson & Johnson from 2006 to 2007 and as the VP-Non Oncology Early Clinical Development at Genentech, Inc. from 2014 to 2015. Dr. Ho also served as an Independent Director at NGM Biopharmaceuticals, Inc. from 2020 to 2024. She has a doctorate degree from Cornell University and an undergraduate degree from Harvard College. |
| John M. Maraganore |
John M. Maraganore is the founder of Orbital Therapeutics, Inc. He currently holds multiple positions including Chief Executive Officer at Jmm Innovations LLC, Chairman at Hemab ApS, Chairman at Aitia, Inc., Director at Termeer Foundation, Independent Outside Director at Takeda Pharmaceutical Co., Ltd., Independent Director at ProKidney Corp., Director at Nucleate Bio, Inc., Director at Mahzi Therapeutics, Inc., Independent Director at Kymera Therapeutics, Inc., Advisor & Venture Partner at Omega Fund Management LLC, Executive Advisor at Blackstone, Inc., Venture Partner at ARCH Venture Partners LLC, and Venture Advisor at Atlas Venture Advisors, Inc. He previously served as the Chief Executive Officer & Director at Alnylam Pharmaceuticals, Inc., Lead Independent Director at Agios Pharmaceuticals, Inc., Director at Regulus Therapeutics, Inc., Director at bluebird bio, Inc., Director-Market & Business Development at Biogen MA, Inc., Director at Molecular Biology Resources, Inc., Director-Molecular Biology & Business Development at Biogen Idec, Inc. (North Carolina), Director at MacroGenics, Inc., Director at Taligen Therapeutics, Inc., Scientist at ZymoGenetics, Inc., Venture Partner at Third Rock Ventures GP LP, Scientist at The Upjohn Co., and Senior VP-Strategic Product Development at Millennium Pharmaceuticals, Inc. He received his undergraduate, graduate, and doctorate degrees from The University of Chicago in 1984, 1985, and 1986 respectively. |
| Mark C. Fishman |
Mark C. Fishman is currently the Lead Independent Director at Beam Therapeutics, Inc. He is also a Director at Aditum Bio Fund 1 LP, Versanis Bio, Inc., Teres Bio, Inc., Anteris Bio, Inc., and The General Hospital Corp. Additionally, he serves as a Trustee-Emeritus at The Children's Hospital of Philadelphia. In his former positions, Dr. Fishman was the Chairman of Novartis Institute for Functional Genomics, Inc. and Semma Therapeutics, Inc. He also served as a Director at Novartis International Pharmaceutical Ltd. and Geneception, Inc. Furthermore, he was a Member-Executive Board at Novartis AG and the Founding President of Novartis Institutes for Biomedical Research, Inc. He was also the Founding Director of the Cardiovascular Research Center and a Professor at Harvard Medical School. Dr. Fishman received his undergraduate degree from Yale University in 1972 and his doctorate from Harvard Medical School in 1976. |
| Kristina Marie Burow |
Kristina Marie Burow is the founder of Sapphire Energy, Inc. (founded in 2007) and Receptos LLC (founded in 2008). She is currently the Managing Director at ARCH Venture Partners LLC and ARCH Venture Partners LP. She also holds director positions at Trelys, Inc., National Venture Capital Association, Scholar Rock, Inc., Scholar Rock Holding Corp., Beam Therapeutics, Inc., Rome Therapeutics, Inc., Autobahn Therapeutics, Inc., RBNC Therapeutics, Inc., Treeline Biosciences, Inc., Neumora Therapeutics, Inc., Pretzel Therapeutics, Inc., and Boundless Bio, Inc. Ms. Burow is also the founder of Orbital Therapeutics, Inc. She has held former director positions at Celgene Corp., Lycera Corp., Kilimanjaro Energy, Inc., Epirium Bio, Inc., LearnZillion, Inc., Limerick BioPharma, Inc., AgBiome INC, BlackThorn Therapeutics, Inc., Metacrine, Inc., Unity Biotechnology, Inc., Sienna Biopharmaceuticals, Inc., Vividion Therapeutics, Inc., Vir Biotechnology, Inc., Reactive Biosciences, Inc., and Gossamer Bio, Inc. She has also worked as an associate at Novartis Bioventure Fund and Novartis Venture Fund, and as a principal at Novartis Institute for Functional Genomics, Inc. Ms. Burow has a graduate degree from The Trustees of Columbia University in The City of New York and Columbia University College of Pharmaceutical Sciences, an undergraduate degree from the University of California, Berkeley, and an MBA from The University of Chicago Booth School of Business. |
| Kathleen E. Walsh |
Kathleen E. Walsh currently holds director positions at Boston Green Ribbon Commission, Emmanuel College, Yale University, Greater Boston Chamber of Commerce, The Association of American Medical Colleges, Summit Health, Inc., Massachusetts Health & Hospital Association, Inc., Boston Public Health Commission, Beam Therapeutics, Inc., Young Men's Christian Association of Greater Boston, Inc., Council of Teaching Hospitals, and Yale School of Medicine. Ms. Walsh has previously held director positions at Boston Medical Center, Guidehouse, Inc., CAE, Inc., LifeMD, Inc., WellCare Health Plans, Inc., Imprivata, Inc., Federal Reserve Bank of Boston, Yale Corp., Pine Street Inn, Inc., Dymedex Consulting LLC, American Hospital Association, Inc., The General Hospital Corp., The Brigham & Women's Hospital, Inc., Novartis Institutes for Biomedical Research, Inc., and Massachusetts General Hospital Cancer Center. Ms. Walsh received her undergraduate and graduate degrees from Yale University. |
| Graham K. Cooper |
Graham K. Cooper is currently the Chairman at Kezar Life Sciences, Inc. and an Independent Director at Beam Therapeutics, Inc. Previously, he served as the Executive Chairman at Applied Molecular Transport, Inc. from 2022 to 2023. He also held the position of Director-Health Care Investment Banking at Deutsche Bank Securities, Inc. from 1997 to 2006. Additionally, he was an Independent Director at Celladon Corp. from 2013 to 2016 and at Unity Biotechnology, Inc. from 2017 to 2022. Mr. Cooper was the Chief Financial Officer & EVP-Business Development at Geron Corp. in 2012 and the Chief Financial Officer, Treasurer & Senior VP at Orexigen Therapeutics, Inc. from 2006 to 2011. He served as the CFO, CAO, Head-Investor & Media Relations at Receptos LLC from 2014 to 2015. Furthermore, he worked as an Accountant at Deloitte & Touche LLP from 1992 to 1995. Mr. Cooper's education includes an undergraduate degree from the University of California, Berkeley and an MBA from Stanford Graduate School of Business. |
